Watching Vaxcyte, Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsExecutive ChangeItem 5.02 · 8-KLOW RiskNeutral
Vaxcyte, Inc.
Filed: Jul 13, 2026CIK: 0001649094
AI Executive Summary
AI-powered analysis of 8-K filing content
Heath Lukatch retired from Vaxcyte's Board of Directors effective July 16, 2026, after over eight years of service. John Mar was appointed to the Board following a recommendation from the Nominating and Corporate Governance Committee.
Key Takeaways
Heath Lukatch's departure is amicable with no disagreements cited, indicating a planned transition rather than a conflict-driven exit
John Mar's appointment suggests the Board is refreshing its composition with new perspectives while maintaining continuity
1 more takeaway
Filing Overview
Form Type8-K
Filing DateJul 13, 2026
Item5.02
CategoryExecutive Change
CIK0001649094
Accession #pcvx-20260713
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
board changeleadership transition
What This Means
A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.